Mind Cure Health Begins Research Into Psychedelic Compounds

Mind Cure Health (CSE: MCUR) has reached a milestone, with the company this morning announcing its translational research program that will initially focus on the compounds of psilocybin, ibogaine, and ketamine. Research into the compounds is said to be largely focused on the treatment of physical and psychological pain and related mental health illnesses.

Translational research in layman terms is multidisciplinary and involves applying lab research and preclinical studies to developing clinical trials and studies in humans. Unlike applied science, translation research is said to be solely focused on improving health outcomes.

The program is intended to enable Mind Cure to investigate the compounds of psilocybin, ketamine and ibogaine for use in pharmaceuticals. All three are said to have demonstrated safety profiles that have a proven efficacy, but the compounds have yet to be optimized for medical use. The research will be focused on “delivering validation of commercially viable medicines, methods and tools to address numerous priorities in treating mental health.”

“Despite social stigmas, many classical psychedelics have safely demonstrated profound therapeutic effectiveness with alleviating all forms of pain associated with neurological trauma and chronic diseases. We begin our research with tremendous promise for new medicines that share structural similarities with improved receptor targeting, dosing, and therapeutic profiles.”

Dr. Ryan Hartwell

The company is currently focused on executing on this approach of research into psychedelics as a means of expediting research and development programs. Further, the program is said to holistically account for the lasting effects on quality of life and clinical outcomes in patients as a result of the mixed effects of physical and psychological pain.

Antimony Resources — sponsored Sponsored · Antimony Resources

Mind Cure Health last traded at $0.65 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver Is in a New Price Regime, and the Market Isn’t Used to It | Keith Neumeyer – First Majestic

Agnico Eagle Just Made a Massive Gold Land Grab

A Copper-Gold Deposit Caught the White House’s Attention | Rob McLeod – Cambria Gold

Recommended

Mercado Drills 256 g/t Silver Over 6.5 Metres In First Drill Hole of Inaugural Program

Antimony Resources Drills 4.38% Sb Over 7.05 Metres At Bald Hill In Final Hole Of 2025 Program

Trending

Related News

Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury

Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one...

Wednesday, February 17, 2021, 07:27:04 AM

Mind Cure Health: A Glance At The Latest Additions To The Advisory Team

Over the course of the last two weeks, Mind Cure Health (CSE: MCUR) has slowly...

Sunday, October 11, 2020, 03:47:00 PM

Mind Cure Appoints Kelsey Ramsden As CEO And President

Mind Cure Health (CSE: MCUR) has shaken up its management team slightly, promoting COO Kelsey...

Tuesday, December 1, 2020, 08:51:06 AM

Mind Cure To Launch Psychedelic Assisted Mental Health Therapy Centre

Mind Cure Health (CSE: MCUR) is the latest issuer to become involved in operating psychedelic-assisted...

Thursday, December 10, 2020, 07:26:09 AM

Mind Cure Appoints Dr Wolfram Tetzlaff To Advisory Board

It appears that Mind Cure Health (CSE: MCUR) is not quite yet done compiling its...

Tuesday, October 13, 2020, 09:01:47 AM